Abstract:3055 Background: Acute lymphoblastic leukemia (ALL) ranks among the most prevalent pediatric cancers. Molecular testing, including cytogenetics, has been widely used for prognosticating pediatric ALL. However, cytogenetic testing in pediatric ALL is incapable of detecting submicroscopic genetic changes and suffers from variable sensitivity, which may lead to heterogeneous outcomes within cytogenetic subgroups. In addition to conventional prognostic biomarkers, long non-coding RNAs (lncRNAs) are expressed in both a disease- and tissue-specific manner, emerging as promising biomarkers. However, well-established lncRNA prognostic biomarkers for pediatric ALL have yet to be identified. Therefore, in this study, we discovered three singular lncRNA prognostic biomarkers and a prognostic panel composed of multi-lncRNAs for pediatric ALL using our newly developed BAMBI method. Methods: This study utilized RNA-seq data from 561 distinct individuals, comprising 647 blood or bone marrow biospecimens obtained from pediatric patients with ALL from the dbGaP TARGET dataset. Among these individuals with RNA-seq and survival data, 25.8% deceased during follow-up. The average age at enrollment was 8.1 years. Of this cohort, 36.0% were female, and 61.5% were Caucasian white. Initially, our lncRNA identification tool, Flnc (Li Z., et al., Noncoding RNA. 2022), was employed to identify and quantify both novel and known lncRNAs expressed in pediatric ALL. Subsequently, our machine-learning based method, BAMBI, was utilized to discover lncRNAs as new prognostic biomarkers in pediatric ALL. Results: Three lncRNAs (ZBTB47 and NKTR antisense RNA, AC097359.2’s new isoform, and a novel lncRNA near STXBP5) were identified as individual putative biomarkers for prognosis. Each of these three lncRNA biomarkers exhibited predictive power for survival, with accuracy ranging from 68.2% to 72.8% and AUROC scores ranging from 67.7% to 75%. Furthermore, we established three lncRNA biomarker panels composed of these three lncRNAs along with a few additional lncRNAs, which showed improved prediction power with accuracy ranging from 78.3% to 79.6%, and AUROC scores ranging from 82.1% to 85.2%. Conclusions: We discovered both singular lncRNA and panels of multi-lncRNAs as prognostic biomarkers of pediatric ALL patients. These putative lncRNA biomarkers could be further validated through independent cohorts or prospective clinical study designs.

Specific lncRNA signatures discriminate childhood acute leukaemias: a pilot study

MicroRNA Expression Signatures Accurately Discriminate Acute Lymphoblastic Leukemia from Acute Myeloid Leukemia.

LINC00958 as new diagnostic and prognostic biomarker of childhood acute lymphoblastic leukaemia of B cells

Transcriptome-wide subtyping of pediatric and adult T cell acute lymphoblastic leukemia in an international study of 707 cases

Identification of Potential Signatures and Their Functions for Acute Lymphoblastic Leukemia: A Study Based on the Cancer Genome Atlas

Expression and Clinical Significance of Long Non-coding RNA AC002454.1 in Children with Acute Leukemia

Discovery of Long Non-Coding RNA Biomarkers for Prognosis in Pediatric Acute Lymphoblastic Leukemia.

A three‑lncRNA signature for prognosis prediction of acute myeloid leukemia in patients.

Long Non-coding RNA RP11-252C15.1 is a Potential Biomarker of Prognosis and Hallmark for Leukemogenesis in Children with B-cell Precursor Acute Lymphoblastic Leukemia

Molecular characterization and biomarker identification in paediatric B-cell acute lymphoblastic leukaemia

Identification of Novel Lncrnas Involved in the Pathogenesis of Childhood Acute Lymphoblastic Leukemia

Data-driven discovery of gene expression markers distinguishing pediatric acute lymphoblastic leukemia subtypes

Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia

Integrative Genomic Analyses Identify LncRNA Regulatory Networks Across Pediatric Leukemias and Solid Tumors.

Uncovering low-dimensional, miR-based signatures of acute myeloid and lymphoblastic leukemias with a machine-learning-driven network approach

Novel lncRNAs LINC01221, RP11-472G21.2 and CRNDE are markers of differential expression in pediatric patients with T cell acute lymphoblastic leukemia

A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients

Long non-coding RNA signatures and related signaling pathway in T-cell acute lymphoblastic leukemia

Microarray Profiling of Bone Marrow Long Non-Coding RNA Expression in Chinese Pediatric Acute Myeloid Leukemia Patients.

Upregulation of the long noncoding RNA GJA9-MYCBP and PVT1 is a potential diagnostic biomarker for acute lymphoblastic leukemia

Human circulating small non-coding RNA signature as a non-invasive biomarker in clinical diagnosis of acute myeloid leukaemia